Object To evaluate the efficacy of three dose levels of the oral hepatobiliary manganese-based magnetic resonance imaging (MRI) contrast agent CMC-001, and assess its safety profile and patient acceptability. Materials and methods After ethics committee approval, 32 healthy volunteers (males/females: 18/14) were included. Liver MRI was performed before and 3 h after ingestion of 0.8, 0.4, and 0.2 g of CMC-001 on separate occasions. Liver-to-muscle signal intensity (SI) ratio from baseline to post-contrast and image quality was assessed. Adverse drug reactions/adverse events (ADRs/AEs) and clinico-laboratory tests were monitored. Results The increase in liver-to-muscle SI ratio was significantly higher after 0.8 g (0.696) compared to 0.4 g (0.458) and 0.2 g (0.223) (in all pair-wise comparisons, P \ 0.0001). The overall image quality was superior after 0.8 g. ADRs/AEs were dose-related and predominantly of mild intensity. Conclusion Liver MRI using 0.8 g CMC-001 has the highest efficacy and still acceptable ADRs and should therefore be preferred.
Introduction
State-of-the-art magnetic resonance imaging (MRI), especially with the use of liver-specific contrast agents, has been shown to be superior to multi-detector computed tomography (MDCT), fluoro-18-deoxyglucose positron emission tomography (FDG-PET), FDG-PET/CT and contrast-enhanced ultrasound for the diagnosis of colorectal cancer liver metastases (CRLM) [1] [2] [3] [4] [5] . Currently used MRI contrast agents with liver-specific properties are administered intravenously and have T1-shortening properties. Two such agents are gadoxetic acid and gadobenate dimeglumine.
A novel manganese-based contrast agent, CMC-001, has been developed for oral administration. The active substance is manganese chloride (MnCl 2 ) tetrahydrate and is combined with alanine and vitamin D 3 serving as promoters for bowel wall absorption. Recently, MnCl 2 has also been combined with ascorbic acid for promoting absorption from the bowel wall [6] . After ingestion, manganese is absorbed by the small bowel and transported via the portal circulation to the liver. Manganese is then taken up by functioning hepatocytes and secreted into the bile duct system. In MRI, this will cause an increase in signal intensity (SI), both of the liver parenchyma and of the bile duct system (on T1-weighted sequences, optimally between 2 and 6 h after ingestion) [7] . Metastases and nonfunctioning hepatocytes do not take up manganese, and thus have low SI on T1-weighted sequences. Furthermore, up to 95% clears from the liver at first-pass. Thus only minimal amounts of manganese reach the systemic circulation, substantially reducing the risk of adverse events (AEs) correlated with the intravenous administration of manganese [8, 9] . This, in combination with the convenience of self-administration of the contrast agent on an outpatient basis, 2-6 h prior to imaging, makes the orally administered CMC-001 an interesting alternative for imaging of liver metastases.
It has been shown that after 1.6 g MnCl 2 , the delineation of liver metastases is improved [10] . Furthermore, the sensitivity of 1.6 g MnCl 2 for detecting CRLM is similar to gadobenate dimeglumine-enhanced MRI [11] . However, in that study, the frequency of gastrointestinal side effects was higher compared to those reported by others, a factor that could eventually prohibit widespread use [10, 12, 13] . Thus, a lower dose, with an acceptable frequency of adverse drug reactions (ADRs), without losing good image quality, has to be found.
The primary aim of our liver MRI study was to evaluate the efficacy of three different doses of the contrast agent CMC-001-namely 0.8, 0.4, and 0.2 g. The secondary aim was to evaluate the safety profile and patient acceptability of CMC-001.
Materials and methods

Study population
Between February and May 2010, 32 healthy volunteers (males/females: 18/14, mean age 24.3, age range 18-48) fulfilled the inclusion criteria and were preliminarily randomized; inclusion and exclusion criteria are presented in Table 1 . Two of them were excluded from the study: one withdrew the approval for personal reasons and one was excluded due to an incidentally found focal nodular hyperplasia (FNH). Both subjects were excluded after administration of one dose level of CMC-001, allowing their inclusion in the safety analysis. In total, 30 volunteers completed the study. The local ethics committee approved the study and all participants provided their written informed consent.
Study design
The study was a single-centre, double-blind, randomized, cross-over, dose-response, phase II study in healthy The CMC-001 sachets were dispensed in ordinary cold tap water and each dose was administered as 200 mL oral solution. In order to ensure the double blindness of the study, a person not otherwise involved in the study prepared the different doses of CMC-001. In addition, a second independent person supervised the whole procedure in order to ensure that the dispensing process was followed correctly.
MRI technique
All MRI scans were performed at 1.5 Tesla (Magnetom Avanto, Siemens Healthcare, Erlangen, Germany), combining spine and flexible body array coils. Every scan included a T1-weighted sequence for study analysis and a T2-weighted sequence for characterization of incidental findings (such as cysts and haemangiomas, should they be present). The 3D T1-weighted sequence was a fat-saturated, volume interpolated breath-hold examination (VIBE), in the axial plane at end inspiration [1.8 mm thick slices, no inter-slice gap, echo time (TE) 1.92 ms, repetition time (TR) 4.29 ms, field of view 35 cm, flip angle 10 degrees, matrix 134 9 256, parallel imaging factor 2]. The VIBE was repeated once to minimize the risk of breathingcorrelated artefacts. The T2-weighted sequence was a respiratory-triggered, half-Fourier acquisition single-shot turbo spin-echo (T2-HASTE), in the axial plane [4 mm thick slices, no inter-slice gap, echo time (TE) 76 ms, repetition time (TR) 1,000 ms, field of view 38 9 28.5 cm].
Image evaluation and definition of efficacy variables
On completion of the study, all images were evaluated in consensus by two radiologists (NA and TB) experienced in abdominal imaging (10 and 6 years, respectively). The evaluation was performed on a PACS workstation (Sectra, Linköping, Sweden). At the time of image evaluation, both radiologists were blinded to the doses given. The efficacy variables were assessed by using the images derived by the T1-weighted sequence, at baseline and post-contrast. Data for assessing the efficacy variables were obtained from volunteers who completed the study (n = 30). There were one primary and six secondary variables.
Primary efficacy variable
The primary efficacy variable was the calculation of the increase in liver-to-muscle signal intensity (SI) ratio from baseline (SI pre ) to post-contrast (SI post ). A circular region of interest (ROI) was placed in corresponding locations at the liver parenchyma and paraspinal musculature on baseline and post-contrast images avoiding degrading artefacts. The following formula was used to calculate the increase in liver-to-muscle signal intensity (SI) ratio:
Secondary efficacy variables
The secondary efficacy variables were:
1. Relative increase in the signal intensity of the liver from baseline to post-contrast: A circular ROI was placed in corresponding locations at the liver parenchyma on baseline and post-contrast images. The following formula was used to calculate the relative increase in liver SI: [(Liver SI post -Liver SI pre )/Liver SI post ] 9 100% 2. Ranking of overall image quality of post-contrast images: Overall image quality was defined as the ability to delineate peripheral small liver vessel branches in combination with the subjectively assessed signal-to-noise ratio (SNR). The image set presenting the most satisfactory overall image quality was ranked superior, the second best intermediate, and the least satisfactory inferior. The window level was automatically optimized for each visit by pressing F1 on the workstation; thereby the mean SI of all image-generating voxels in the image was set as the window level (WL) while 4 times their standard deviation was used as the window width (WW). 3. Overall contrast medium uptake in the liver: The window level was the same for all visits, and was the same automatic optimized level and width of the precontrast series (as described above). The assessment was performed subjectively and the uptake was defined in a four-point scale as excellent, good, fair or poor. 4. Homogeneity of contrast medium uptake in the liver:
The assessment was performed subjectively and the homogeneity was defined in a three-point scale as homogeneous, slightly inhomogeneous or patchy.
Assessment of safety variables
For the evaluation of safety and acceptability of CMC-001, the following variables were assessed based on data obtained from individuals who were exposed to at least one dose level of CMC-001 (i.e. the 30 individuals that completed the study and the 2 individuals that were excluded from the efficacy evaluation):
1. Adverse events. Monitoring of occurrence and followup of AEs was done at 1, 2 and 3 h after contrast administration on each visit. Furthermore, after the participants left the imaging suite, they were contacted by telephone at 24, and 48 h and on day 6 after contrast administration. The investigator judged all AEs as mild, moderate or severe. ADRs are those AEs that are possibly or probably related to the administration of CMC-001. 2. Physical examination before and 3 h after contrast administration. The physical examination included the evaluation of the volunteer's general appearance, mouth and throat, heart, lungs, abdomen and neurological system (assessed as normal or abnormal; in case of abnormal findings, these were classified as clinically significant or not). 3. Vital signs (blood pressure and heart rate) before and at 1, 2 and 3 h after contrast administration. 
Statistical analysis
An analysis of variance (ANOVA) for the cross-over design was used to compare dose levels for the primary variable. Since the result from the carry-over test was not significant on a 5% level, a model without carry-over effects was used to make pair-wise comparisons between the dose levels. Adjustment of the statistical significance level was made using the Hochberg's method. The nonparametric Wilcoxon signed-rank test was performed as a sensitivity analysis of the pair-wise comparisons for the primary variable. Multiple comparisons of continuous data were performed by ANOVA. In the case of a statistically significant result in the ANOVA, statistical comparisons were made using the post hoc test proposed by Fisher to control for multiplicity. In order to test differences between two independent groups, statistical comparisons were made using the Student's t test for uncorrelated means, after validation for normal distribution by means of the ShapiroWilk test. In order to evaluate hypotheses of variables in contingency tables, the Chi-square test was used or, in the case of small expected frequencies, Fisher's exact test. In addition to that, descriptive statistics were used to characterize the data. All analyses were performed using SAS statistic software (The SAS system for Windows 9.2, SAS Institute Inc., Cary, NC, USA). A P value of \0.05 was considered as significant and in the case of a statistically significant result the P value has been given.
Results
Efficacy
Primary variable
The increase in liver-to-muscle SI ratio from baseline to post-contrast was most pronounced at the 0.8 g dose level (mean increase: 0.696; standard deviation, SD: 0.238), followed by the 0.4 g dose level (0.458; 0.272) and 0.2 g dose level (0.223; 0.143) (Fig. 1) ; there was statistical significance (P \ 0.0001) in all three pair-wise comparisons (Table 2) .
Secondary variables
1. Relative increase in liver SI from baseline to postcontrast: The mean relative increase in liver SI was higher for the 0.8 g dose level (57%) compared to the 0.4 g dose level (33%) and the 0.2 g dose level (19%). There was statistical significance (P \ 0.05) in all three pair-wise comparisons (Table 2) . , with all comparisons between the three dose levels being statistically significant (P \ 0.05) ( Table 3) . A typical example of examination ranking with regard to overall image quality is presented in Fig. 2. 3. Overall contrast medium uptake in the liver: 93% of participants (28 of 30) showed better results in overall contrast medium uptake in the liver at the 0.8 g and 57% (17 of 30) at the 0.4 g dose levels compared to the 0.2 g dose level (P \ 0.001 and P [ 0.05, respectively). At the 0.8 g dose level, 70% of participants (21 of 30) showed better results compared to the 0.4 g dose level (P \ 0.01). A typical example of rating the overall contrast medium uptake in the liver is presented in Fig. 3 . 4. Homogeneity of contrast medium uptake in the liver:
Irrespective of dose level, most participants had the same results for homogeneity of contrast medium uptake in the liver. Safety 1. Adverse events: A total of 89 AEs were reported in the study ( Table 4 ). The most common AEs were gastrointestinal disorders (diarrhoea, 19; nausea, 19; flatulence, 9), followed by nervous system disorders (headache, 9). Sixty-two of these 89 were considered to be ADRs. The number of participants with at least one ADR increased with increasing dose level. Likewise, the number of unique ADRs increased with increasing dose level ( Table 4 ). All cases of diarrhoea, all but two cases of nausea, all cases of flatulence and 2 of the 9 reported cases of headache were considered to be ADRs (Table 5 ). Of the 89 AEs reported in the study only two were considered to be severe in intensity (Table 6 ). These were two cases of diarrhoea (1 at the 0.8 g dose level and 1 at the 0.2 g dose level), and both were considered ADRs. Eight were considered ADRs with moderate intensity (diarrhoea 3; nausea 2; flatulence 2; vomiting 1). There were no serious ADRs leading to discontinuation of the investigational product. 2. Physical examination: No clinically significant abnormalities were recorded in the study. 3. Vital signs (blood pressure, heart rate): No clinically significant abnormalities were recorded in the study.
Electrocardiogram (ECG): No clinically significant
abnormalities were recorded in the study. 5. Clinical laboratory evaluation (standard safety parameters): Occasional out-of-range values were observed for the clinical chemistry, haematology and urinalysis parameters assessed in the study. Of these, some were considered to be possibly related to the administration of CMC-001: white blood cell elevation of mild intensity was observed after receiving the 0.4 g dose level (2 participants) and the 0.8 g dose level (2 participants). 
Discussion
This study of the oral hepatobiliary contrast agent CMC-001 shows that the efficacy of the 0.8 g dose level is higher than the dose level of 0.4 and 0.2 g. The differences were statistically significant, with the highest increase in liverto-muscle SI ratio seen after administration of the 0.8 g dose level. This increase in SI of the liver parenchyma made it easier to delineate small vessels in the periphery of the liver at the 0.8 g dose level compared to 0.4 and 0.2 g, resulting in a higher ranking of the 0.8 g dose level images with regard to the overall image quality. The appearance of colorectal cancer liver metastases resembles that of dark vessels [11] . Thus, one can assume that if small peripheral vessels are clearly defined, then even metastases of similarly small size could be detected and delineated. The 0.8 g dose level, with its significantly better efficacy, is therefore preferred with regard to image quality. Regarding the safety results (the secondary objective of the study), no safety concerns were identified in terms of reported ADRs and AEs, clinically relevant abnormalities or trends in physical examination, vital signs, ECG, laboratory values or manganese blood concentration. There was, however, an increase of manganese blood concentration with increasing dose levels. This indicates that small amounts of manganese do reach the systemic circulation. However, the blood levels of manganese did not exceed the reference values. Furthermore, there were differences in the frequency of reported ADRs/AEs between the three different dose levels assessed, where a greater number of ADRs/AEs were observed with increasing dose level. The most common AE was diarrhoea, followed by nausea, flatulence, and headache. Of the 89 AEs reported in the study, 74 were considered mild, 13 moderate and 2 severe in intensity. The 2 AEs reported as severe were cases of diarrhoea (0.8 and 0.2 g dose levels). The participant with severe diarrhoea after administration of 0.8 g reported diarrhoea of mild intensity before the CMC-001 administration; thus, the diarrhoea worsened after CMC-001 administration. The participant with severe diarrhoea after 0.2 g had no diarrhoea after administration of the higher dose levels. In a previous study conducted by our group [11] , side effects following administration of 1.6 g of CMC-001 occurred in 19 out of 20 patients (95%) with the most common AEs being diarrhoea (n = 12) and nausea (n = 4); these side effects occurred in a relatively higher frequency than those reported by others [10, 12, 13] . In the current study, side effects following the administration of a 0.8 g dose occurred in 25 of 31 patients (81%). None of the ADRs led to discontinuation of the investigational product, and none required hospitalization or medication, with the exception of mild analgesics for headache. Thus, the lowest dose, i.e. 0.2 g, has the lowest frequency and intensity of occurring ADRs/AEs. However, the 0.8 g dose level of CMC-001 is relatively well tolerated.
In the current study, three different dose levels of the contrast agent CMC-001 were evaluated (0.8, 0.4, and 0.2 g dose levels). The reason for not including the 1.6 g dose level was the relatively high frequency of gastrointestinal side effects we had previously encountered, as mentioned earlier. Interestingly, in a recent study by Rief et al. [7] the authors could not observe any statistically significant difference in liver signal intensity enhancement or liver-to-lesion contrast between the 0.8 and 1.6 g dose levels in patients with liver metastases from various primary malignancies. The results of Rief et al. contradict those from a previously published study by Chabanova et al. [14] where it was shown that the 1.6 g dose level caused a more pronounced increase in SI of liver compared to the 0.8 g dose level. The study by Chabanova has, however, a clearly different study design. As Rief et al. point out, the results of their study are preliminary and should be further validated in a larger number of subjects. It is, anyhow, an indication that the 0.8 g dose level may suffice in the clinical setting, justifying our choice not to include the 1.6 g dose level in the current evaluation. One limitation of the study is that the study population was comprised of healthy young volunteers, as opposed to the intended target patient group, namely patients with CRLM. Data available from our previous study of patients with CRLM show that there is no uptake of CMC-001 contrast agent in metastases, muscle or liver vessels [11] . This allows the use of muscle as an internal reference and liver vessels as a substitute for CRLM when evaluating the liver of healthy volunteers, which indicates that our results can be applicable to patients with CRLM. One possible further limitation is that a safety analysis separately for each promoter for bowel wall absorption, i.e. alanine and vitamin D 3 , was not performed. However, there are no data in the literature suggesting that these two promoters -in the amounts used for the three doses of CMC-001 tested in the current study-would pose any safety concerns. Namely, alanine is included in the FDA's list of nutrients and dietary supplements that are generally recognized as safe [15] and for vitamin D 3 , the lowest observed adverse effect level (LOAEL) is 3,800 IU per day being well above 800 IU, which was the highest level used in the current study [16] .
In conclusion, the 0.8 g dose level of the orally administered manganese-based contrast agent CMC-001 provides clearly higher SI enhancement and better imaging quality compared to the 0.4 and 0.2 g dose levels, thus rendering the 0.8 g dose level the most efficacious of the three. This is at the expense of more frequent ADRs/AEs, which are, however, predominantly of mild intensity and should be endurable for the intended patient group. The use of CMC-001 raises no safety concerns and the use of the 0.8 g dose level is recommended ahead of those of 0.4 and 0.2 g.
